
LQDA Stock Forecast & Price Target
LQDA Analyst Ratings
Bulls say
Liquidia Corp's recent performance indicates a significant growth trajectory, with an approximate increase in inhaled treprostinil market share from 10% in Q3 to 17%. The strategic decision to expand the sales force by one-third aims to enhance product awareness in a less competitive market, particularly for pulmonary hypertension associated with interstitial lung disease (PH-ILD). Additionally, positive Phase 3 data for the investigational L606 formulation demonstrates a favorable tolerability profile, reinforcing the company’s competitive positioning within the pulmonary hypertension treatment landscape and highlighting its potential for sustained growth.
Bears say
Liquidia Corp is facing significant challenges that contribute to a negative outlook on its stock. The company's primary product, YUTREPIA, has experienced a decline in sales of 11% quarter-over-quarter and is projected to underperform upon its anticipated full approval in 2025 due to limited differentiation from competitor products, cash constraints, and inadequate commercial infrastructure. Additionally, ongoing legal risks surrounding YUTREPIA's exclusivity and potential unfavorable outcomes from patent litigation could severely impact the company's prospects, including the risk of royalty obligations and constraints on the development of its investigational product, L606.
This aggregate rating is based on analysts' research of Liquidia Technologies Inc and is not a guaranteed prediction by Public.com or investment advice.
LQDA Analyst Forecast & Price Prediction
Start investing in LQDA
Order type
Buy in
Order amount
Est. shares
0 shares